FATE

FATE Therapeutics Inc

NASDAQ· Healthcare· Biotechnology

$2.43-4.33%

Key metrics

Market cap: $291.16M
P/E: —
Forward P/E: —
P/B: 1.8x
Dividend yield: —
EPS: -$1.01
ROE: -60.75%
Profit margin: 0.00%
Revenue growth: +9.20%
Beta: 2.55
52-week high: $3.23
52-week low: $0.93

History

How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.

Equity, revenue and profitEquityRevenueNet income

The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.

Revenue4 years

Net debtDebt minus cash — below zero means more cash than debt

Investors holding this

Major managers that reported this stock in their latest 13F.

About the company

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Employees: 161
Headquarters: San Diego, United States
Website: fatetherapeutics.com

Company description provided by Yahoo Finance.